Selected research
Industry Research
Renin-Angiotensin-System (RAS)-Acting Agent Industry Research Report 2026
Market perspective
The global Renin-Angiotensin-System (RAS)-Acting Agent market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Renin-Angiotensin-System (RAS)-Acting Agent is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Renin-Angiotensin-System (RAS)-Acting Agent is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Renin-Angiotensin-System (RAS)-Acting Agent is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Renin-Angiotensin-System (RAS)-Acting Agent include Takeda Pharmaceutical Company Limited, Sanofi S.A., Johnson & Johnson, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Daiichi Sankyo Company,Limited, AstraZeneca plc and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Renin-Angiotensin-System (RAS)-Acting Agent market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Renin-Angiotensin-System (RAS)-Acting Agent Market by Company
Takeda Pharmaceutical Company Limited
Sanofi S.A.
Johnson & Johnson
Novartis AG
Merck & Co., Inc.
Pfizer, Inc.
Daiichi Sankyo Company,Limited
AstraZeneca plc
Bristol-Myers Squibb Company
Boehringer lngelheim GmbH
Renin-Angiotensin-System (RAS)-Acting Agent Segment by Type
Angiotensin Converting Enzyme Inhibitors (ACEi)
Angiotensin Receptor Blockers (ARBs)
Renin-Angiotensin-System (RAS)-Acting Agent Segment by Application
Heart Failure
Chronic Kidney Disease
Hypertension
Other
Renin-Angiotensin-System (RAS)-Acting Agent Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Renin-Angiotensin-System (RAS)-Acting Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Renin-Angiotensin-System (RAS)-Acting Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Renin-Angiotensin-System (RAS)-Acting Agent.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Renin-Angiotensin-System (RAS)-Acting Agent manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Renin-Angiotensin-System (RAS)-Acting Agent by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Renin-Angiotensin-System (RAS)-Acting Agent in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Angiotensin Converting Enzyme Inhibitors (ACEi)
- Angiotensin Receptor Blockers (ARBs)
Applications
- Heart Failure
- Chronic Kidney Disease
- Hypertension
- Other
Companies covered
- Takeda Pharmaceutical Company Limited
- Sanofi S.A.
- Johnson & Johnson
- Novartis AG
- Merck & Co., Inc.
- Pfizer, Inc.
- Daiichi Sankyo Company,Limited
- AstraZeneca plc
- Bristol-Myers Squibb Company
- Boehringer lngelheim GmbH
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size (2021-2032)
- 2.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales (2021-2032)
- 2.2.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Average Price (2021-2032)
- 2.3 Renin-Angiotensin-System (RAS)-Acting Agent by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Angiotensin Converting Enzyme Inhibitors (ACEi)
- 2.3.3 Angiotensin Receptor Blockers (ARBs)
- 2.4 Renin-Angiotensin-System (RAS)-Acting Agent by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Heart Failure
- 2.4.3 Chronic Kidney Disease
- 2.4.4 Hypertension
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue of Manufacturers (2021-2026)
- 3.4 Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price by Manufacturers (2021-2026)
- 3.5 Global Renin-Angiotensin-System (RAS)-Acting Agent Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Renin-Angiotensin-System (RAS)-Acting Agent, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Renin-Angiotensin-System (RAS)-Acting Agent, Product Type & Application
- 3.8 Global Manufacturers of Renin-Angiotensin-System (RAS)-Acting Agent, Established Date
- 3.9 Global Renin-Angiotensin-System (RAS)-Acting Agent Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda Pharmaceutical Company Limited
- 4.1.1 Takeda Pharmaceutical Company Limited Company Information
- 4.1.2 Takeda Pharmaceutical Company Limited Business Overview
- 4.1.3 Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
- 4.1.5 Takeda Pharmaceutical Company Limited Recent Developments
- 4.2 Sanofi S.A.
- 4.2.1 Sanofi S.A. Company Information
- 4.2.2 Sanofi S.A. Business Overview
- 4.2.3 Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
- 4.2.5 Sanofi S.A. Recent Developments
- 4.3 Johnson & Johnson
- 4.3.1 Johnson & Johnson Company Information
- 4.3.2 Johnson & Johnson Business Overview
- 4.3.3 Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
- 4.3.5 Johnson & Johnson Recent Developments
- 4.4 Novartis AG
- 4.4.1 Novartis AG Company Information
- 4.4.2 Novartis AG Business Overview
- 4.4.3 Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
- 4.4.5 Novartis AG Recent Developments
- 4.5 Merck & Co., Inc.
- 4.5.1 Merck & Co., Inc. Company Information
- 4.5.2 Merck & Co., Inc. Business Overview
- 4.5.3 Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
- 4.5.5 Merck & Co., Inc. Recent Developments
- 4.6 Pfizer, Inc.
- 4.6.1 Pfizer, Inc. Company Information
- 4.6.2 Pfizer, Inc. Business Overview
- 4.6.3 Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
- 4.6.5 Pfizer, Inc. Recent Developments
- 4.7 Daiichi Sankyo Company,Limited
- 4.7.1 Daiichi Sankyo Company,Limited Company Information
- 4.7.2 Daiichi Sankyo Company,Limited Business Overview
- 4.7.3 Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
- 4.7.5 Daiichi Sankyo Company,Limited Recent Developments
- 4.8 AstraZeneca plc
- 4.8.1 AstraZeneca plc Company Information
- 4.8.2 AstraZeneca plc Business Overview
- 4.8.3 AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
- 4.8.5 AstraZeneca plc Recent Developments
- 4.9 Bristol-Myers Squibb Company
- 4.9.1 Bristol-Myers Squibb Company Company Information
- 4.9.2 Bristol-Myers Squibb Company Business Overview
- 4.9.3 Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
- 4.9.5 Bristol-Myers Squibb Company Recent Developments
- 4.10 Boehringer lngelheim GmbH
- 4.10.1 Boehringer lngelheim GmbH Company Information
- 4.10.2 Boehringer lngelheim GmbH Business Overview
- 4.10.3 Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
- 4.10.5 Boehringer lngelheim GmbH Recent Developments
5 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Scenario by Region
- 5.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region: 2021-2032
- 5.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region: 2021-2026
- 5.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region: 2027-2032
- 5.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region: 2021-2032
- 5.3.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region: 2021-2026
- 5.3.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region: 2027-2032
- 5.4 North America Renin-Angiotensin-System (RAS)-Acting Agent Market Facts & Figures by Country
- 5.4.1 North America Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021-2032)
- 5.4.3 North America Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Renin-Angiotensin-System (RAS)-Acting Agent Market Facts & Figures by Country
- 5.5.1 Europe Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021-2032)
- 5.5.3 Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Market Facts & Figures by Country
- 5.6.1 Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Renin-Angiotensin-System (RAS)-Acting Agent Market Facts & Figures by Country
- 5.7.1 South America Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021-2032)
- 5.7.3 South America Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021-2032)
- 6.1.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2021-2032)
- 6.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2021-2032)
- 6.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Type (2021-2032)
- 6.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021-2032)
- 7.1.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Application (2021-2032)
- 7.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2021-2032)
- 7.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Application (2021-2032)
- 7.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Renin-Angiotensin-System (RAS)-Acting Agent Value Chain Analysis
- 8.1.1 Renin-Angiotensin-System (RAS)-Acting Agent Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Renin-Angiotensin-System (RAS)-Acting Agent Production Mode & Process
- 8.2 Renin-Angiotensin-System (RAS)-Acting Agent Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Renin-Angiotensin-System (RAS)-Acting Agent Distributors
- 8.2.3 Renin-Angiotensin-System (RAS)-Acting Agent Customers
9 Global Renin-Angiotensin-System (RAS)-Acting Agent Analyzing Market Dynamics
- 9.1 Renin-Angiotensin-System (RAS)-Acting Agent Industry Trends
- 9.2 Renin-Angiotensin-System (RAS)-Acting Agent Industry Drivers
- 9.3 Renin-Angiotensin-System (RAS)-Acting Agent Industry Opportunities and Challenges
- 9.4 Renin-Angiotensin-System (RAS)-Acting Agent Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst